KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Free Cash Flow (2016 - 2025)

CRISPR Therapeutics AG's Free Cash Flow history spans 11 years, with the latest figure at -$93.1 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 91.75% year-over-year to -$93.1 million; the TTM value through Dec 2025 reached -$345.9 million, down 142.03%, while the annual FY2025 figure was -$345.9 million, 142.03% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$93.1 million at CRISPR Therapeutics AG, down from -$84.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $806.5 million in Q2 2021 and bottomed at -$151.6 million in Q2 2022.
  • The 5-year median for Free Cash Flow is -$95.6 million (2021), against an average of -$41.3 million.
  • The largest annual shift saw Free Cash Flow surged 2435.29% in 2021 before it crashed 215.14% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$95.2 million in 2021, then crashed by 52.9% to -$145.6 million in 2022, then skyrocketed by 34.03% to -$96.0 million in 2023, then surged by 49.46% to -$48.5 million in 2024, then crashed by 91.75% to -$93.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Free Cash Flow are -$93.1 million (Q4 2025), -$84.7 million (Q3 2025), and -$114.0 million (Q2 2025).